Agenus (AGEN) Income from Non-Controlling Interests (2013 - 2026)
Agenus (AGEN) posted quarterly Income from Non-Controlling Interests of -$20000.0 for Q1 2026, up 98.19% year-over-year from -$10091.4 in Q1 2025, and up 41.18% quarter-over-quarter from -$34000.0 in Q4 2025.
Powered by 
Analysis
Agenus (AGEN) Income from Non-Controlling Interests (2013 - 2026) Analysis & Trends
Agenus' Income from Non-Controlling Interests history runs 11 years deep, the most recent figure standing at -$20000.0 for Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests rose 98.19% year-over-year to -$20000.0; the TTM figure through Mar 2026 stood at -$2.1 million (up 53.99% YoY), while the FY2025 annual figure was -$3.2 million, up 36.79% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$20000.0, up from -$34000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was -$3000.0 in Q3 2025, with the low at -$4.4 million in Q2 2023.
- The 5-year median for Income from Non-Controlling Interests is -$2.1 million (2025), against an average of -$1.8 million.
- The sharpest annual moves came in 2022 and 2025: Income from Non-Controlling Interests slumped 299.57% in 2022, then surged 99.64% in 2025.
- Agenus' Income from Non-Controlling Interests stood at -$3.0 million in 2022, then climbed by 23.83% to -$2.3 million in 2023, then surged by 58.68% to -$947000.0 in 2024, then surged by 96.41% to -$34000.0 in 2025, then soared by 41.18% to -$20000.0 in 2026.
- Business Quant data shows AGEN's Income from Non-Controlling Interests at -$20000.0 in Q1 2026, -$34000.0 in Q4 2025, and -$3000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Agenus | 343.11 Mn | 343.11 Mn | 34.52 Mn | -17,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17,000.00 |
| Mar 31, 2026 | -20,000.00 |
| Dec 31, 2025 | -34,000.00 |
| Sep 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -2.06 Mn |
| Mar 31, 2025 | -1.10 Mn |
| Dec 31, 2024 | -947,000.00 |
| Sep 30, 2024 | -828,000.00 |
| Jun 30, 2024 | -1.72 Mn |
| Mar 31, 2024 | -1.57 Mn |
| Dec 31, 2023 | -2.29 Mn |
| Sep 30, 2023 | -2.33 Mn |
| Jun 30, 2023 | -4.41 Mn |
| Mar 31, 2023 | -2.64 Mn |
| Dec 31, 2022 | -3.01 Mn |
| Sep 30, 2022 | -2.49 Mn |
| Jun 30, 2022 | -2.80 Mn |
| Mar 31, 2022 | -2.28 Mn |
| Dec 31, 2021 | -2.10 Mn |
| Sep 30, 2021 | -1.28 Mn |